CAMBRIDGE, MASS., June 7 /CNW/ - Biogen Idec (NASDAQ: BIIB) announced
today that Marijn E. Dekkers, Ph.D., President and Chief Executive Officer
(CEO) of Thermo Fisher Scientific, has been elected to the Biogen Idec Board
of Directors. The election took place at the company's annual shareholder
meeting on May 31, 2007.
"Marijn Dekkers has the scientific background and proven business skills
to provide strategic leadership and guidance as we build on our record of
growth and success in delivering significant therapies for patients," stated
James C. Mullen, President and CEO of Biogen Idec.
"We are pleased that Marijn Dekkers has joined the Biogen Idec Board of
Directors and look forward to working with him," said Bruce Ross, Biogen
Idec's Chairman. "Through his experience at Thermo Electron and now Thermo
Fisher Scientific, he brings a key understanding of how businesses must seize
opportunities to maintain industry leadership."
Prior to the merger of Thermo Electron Corporation and Fisher Scientific
International in November 2006, Dekkers was President and CEO of Thermo
Electron, a position he held since November 2002. During this time, Dekkers
led the consolidation of dozens of independent businesses into a fully
integrated company focused on the analytical instruments industry. He joined
Thermo Electron in July 2000 as chief operating officer.
Dekkers was previously employed at Honeywell International (formerly
AlliedSignal), where he held a number of executive positions. He began his
career as a research scientist within General Electric's corporate R&D center.
A native of the Netherlands, Dekkers received both doctorate and master's
degrees in chemical engineering from the University of Eindhoven and a
bachelor's degree in chemistry from the University of Nijmegen.
About Biogen Idec
Biogen Idec creates new standards of care in therapeutic areas with high
unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the
discovery, development, manufacturing, and commercialization of innovative
therapies. Patients in more than 90 countries benefit from Biogen Idec's
significant products that address diseases such as lymphoma, multiple
sclerosis, and rheumatoid arthritis. For product labeling, press releases and
additional information about the company, please visit, www.biogenidec.com.
For further information:
For further information: Biogen Idec Media Contact: Jose Juves,
617-914-6524 Director Public Affairs or Investment Community Contact:
Elizabeth Woo, 617-679-2812 Vice President Investor Relations